Evidence map›Paper›PMID 26667837›Full record

ArticleInfection and immunity2015

Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium.

C B Lupiañez, L M Canet, A Carvalho, L Alcazar-Fuoli, J Springer, M Lackner, J Segura-Catena, A Comino, C Olmedo, R Ríos and 20 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Polymorphisms within theJournal of fungi (Basel, Switzerland) · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 5 countries.

C B LupiañezGenomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
L M CanetGenomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
A CarvalhoLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
L Alcazar-FuoliMycology Reference Laboratory, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain.
J SpringerUniversitätsklinikum Würzburg, Medizinische Klinik II, Würzburg, Germany.
M LacknerDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
J Segura-CatenaGenomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
A CominoExperimental Research Unit, Virgen de las Nieves University Hospital, Granada, Spain.
C OlmedoExperimental Research Unit, Virgen de las Nieves University Hospital, Granada, Spain.
R RíosGenomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
A Fernández-MontoyaBlood Transfusion Regional Centre and Sectorial Tissue Bank, Granada, Spain.
M Cuenca-EstrellaMycology Reference Laboratory, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain.
C SolanoHematology Department, Clinic University Hospital of Valencia, Valencia, Spain.
M Á López-NevotImmunology Department, Virgen de las Nieves University Hospital, Granada, Spain.
C CunhaLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
A Oliveira-CoelhoLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
T VillaescusaHematology Department, University Hospital of Salamanca, Salamanca, Spain Hematology Department, Jiménez Díaz Foundation, Madrid, Spain.
L FianchiIstituto di Ematologia, Università Cattolica del S. Cuore, Rome, Italy.
J M AguadoUnit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.
L PaganoIstituto di Ematologia, Università Cattolica del S. Cuore, Rome, Italy.
E López-FernándezHematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
L PotenzaDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy.
M LuppiDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy.
C Lass-FlörlDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
J LoefflerUniversitätsklinikum Würzburg, Medizinische Klinik II, Würzburg, Germany.
H EinseleUniversitätsklinikum Würzburg, Medizinische Klinik II, Würzburg, Germany.
L VazquezHematology Department, University Hospital of Salamanca, Salamanca, Spain.
PCRAGA Study Group
M JuradoGenomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain.
J SainzGenomic Oncology Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain Hematology Department, Virgen de las Nieves University Hospital, Granada, Spain juan.sainz@genyo.es.
Hospital Universitario Virgen de las Nieves · ESUniversitätsklinikum Würzburg · DEUniversity of Minho · PTInnsbruck Medical University · ATInstituto de Salud Carlos III · ESUniversidad de Salamanca · ESUniversità Cattolica del Sacro Cuore · ITUniversity of Modena and Reggio Emilia · ITBanc de Sang i Teixits · ESHospital Clínico Universitario de Valencia · ESResearch Institute Hospital 12 de Octubre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies suggest that immune-modulating single-nucleotide polymorphisms (SNPs) influence the risk of developing cancer-related infections. Here, we evaluated whether 36 SNPs within 14 immune-related genes are associated with the risk of invasive aspergillosis (IA) and whether genotyping of these variants might improve disease risk prediction. We conducted a case-control association study of 781 immunocompromised patients, 149 of whom were diagnosed with IA. Association analysis showed that the IL4Rrs2107356 and IL8rs2227307 SNPs (using dbSNP numbering) were associated with an increased risk of IA (IL4Rrs2107356 odds ratio [OR], 1.92; 95% confidence interval [CI], 1.20 to 3.09; IL8rs2227307 OR, 1.73; 95% CI, 1.06 to 2.81), whereas the IL12Brs3212227 and IFNγrs2069705 variants were significantly associated with a decreased risk of developing the infection (IL12Brs3212227 OR, 0.60; 95% CI, 0.38 to 0.96; IFNγrs2069705 OR, 0.63; 95% CI, 0.41 to 0.97). An allogeneic hematopoietic stem cell transplantation (allo-HSCT)-stratified analysis revealed that the effect observed for the IL4Rrs2107356 and IFNγrs2069705 SNPs was stronger in allo-HSCT (IL4Rrs2107356 OR, 5.63; 95% CI, 1.20 to 3.09; IFNγrs2069705 OR, 0.24; 95% CI, 0.10 to 0.59) than in non-HSCT patients, suggesting that the presence of these SNPs renders patients more vulnerable to infection, especially under severe and prolonged immunosuppressive conditions. Importantly, in vitro studies revealed that carriers of the IFNγrs2069705C allele showed a significantly increased macrophage-mediated neutralization of fungal conidia (P = 0.0003) and, under stimulation conditions, produced higher levels of gamma interferon (IFNγ) mRNA (P = 0.049) and IFNγ and tumor necrosis factor alpha (TNF-α) cytokines (P value for 96 h of treatment with lipopolysaccharide [PLPS-96 h], 0.057; P value for 96 h of treatment with phytohemagglutinin [PPHA-96 h], 0.036; PLPS+PHA-96 h = 0.030; PPHA-72 h = 0.045; PLPS+PHA-72 h = 0.018; PLPS-96 h = 0.058; PLPS+PHA-96 h = 0.0058). Finally, we also observed that the addition of SNPs significantly associated with IA to a model including clinical variables led to a substantial improvement in the discriminatory ability to predict disease (area under the concentration-time curve [AUC] of 0.659 versus AUC of 0.564; P-2 log likehood ratio test = 5.2 · 10(-4) and P50.000 permutation test = 9.34 · 10(-5)). These findings suggest that the IFNγrs2069705 SNP influences the risk of IA and that predictive models built with IFNγ, IL8, IL12p70, and VEGFA variants can used to predict disease risk and to implement risk-adapted prophylaxis or diagnostic strategies.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAdultAgedAllelesAspergillosisCase-Control StudiesFemaleGenotypeHumansImmunocompromised HostInterferon-gammaInterleukin-12 Subunit p40Interleukin-4 Receptor alpha SubunitInterleukin-8MaleIL12B protein, humanIL4R protein, humanInterferon-gammaInterleukin-12 Subunit p40Interleukin-4 Receptor alpha SubunitInterleukin-8

Identifiers

PMID26667837
PMCPMC4771352
OpenAlexW2219758163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.